EMA encourages companies to submit type I variations by end- November
Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021
Marketing authorisation holders are advised to submit any type IB variations or groupings of type IBs and type IAs by 3rd December 2021 for a start of procedure in 2021
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
Generalized pustular psoriasis is characterized by episodes of widespread eruptions of painful, sterile pustules
The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
Kymriah, the first-ever FDA-approved CAR-T cell therapy, is currently available in 30 countries in one or more indications
Combination of hardware and data analytics software improves real-time and remote patient monitoring; digitizes and automates time-consuming and critical tasks for medical personnel, reducing administrative tasks by 35 per cent
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
Following the review of around 20 candidate vaccines by the external advisory group, MVC's vaccine was selected as one of two to be included in the global trial
Filing marks first protein-based vaccine submitted to MHRA for authorization
Through the mission an entire ecosystem for services from treatment to critical research will be created in every corner of the country
Subscribe To Our Newsletter & Stay Updated